FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

MARIO SCARTOZZI

Research Profile

Procedures

Disorders

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
MARIO SCARTOZZI; M Bianconi; A Bittoni; L Burattini; M Del Prete; L Faloppi; R Giampieri; Cristian Loretelli; E Maccaroni; D Minardi; R Montironi; G Muzzonigro; S Nicoletti; Stefano Cascinu
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Alessandro Bittoni; Maristella Bianconi; Michela Del Prete; Luca Faloppi; Riccardo Giampieri; Elena Maccaroni; MARIO SCARTOZZI; Stefano Cascinu
The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language?
MARIO SCARTOZZI; R Silva; alberto zaniboni; Italo Bearzi; S Biagetti; T Biscotti; Alfredo Falcone; Eva Galizia; R Giampieri; Lucio Giustini; Fotios Loupakis; E Maccaroni; Alessandra Mandolesi; Stefano Cascinu
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of MARIO SCARTOZZI (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: MARIO SCARTOZZI; M Bianconi; A Bittoni; L Burattini; M Del Prete; L Faloppi; R Giampieri; Cristian Loretelli; E Maccaroni; D Minardi; R Montironi; G Muzzonigro; S Nicoletti; Stefano Cascinu
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
British journal of cancer 2013;108(5):1126-32.
2013: Alessandro Bittoni; Maristella Bianconi; Michela Del Prete; Luca Faloppi; Riccardo Giampieri; Elena Maccaroni; MARIO SCARTOZZI; Stefano Cascinu
The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language?
Critical reviews in oncology/hematology 2013;85(3):332-41.
2012: MARIO SCARTOZZI; R Silva; alberto zaniboni; Italo Bearzi; S Biagetti; T Biscotti; Alfredo Falcone; Eva Galizia; R Giampieri; Lucio Giustini; Fotios Loupakis; E Maccaroni; Alessandra Mandolesi; Stefano Cascinu
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(7):1706-12.
2012: MARIO SCARTOZZI; Laura Belvederesi; M Bianconi; A Bittoni; M Del Prete; L Faloppi; Eva Galizia; R Giampieri; Cristian Loretelli; E Maccaroni; Stefano Cascinu
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
British journal of cancer 2012;106(5):799-804.
2012: Maristella Bianconi; Alessandro Bittoni; Luciano Burattini; Michela Del Prete; Luca Faloppi; Riccardo Giampieri; Elena Maccaroni; MARIO SCARTOZZI; Stefano Cascinu
Angiogenetic pathway as a therapeutic target in renal cell carcinoma.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2012;34(1):15-22.
2012: MARIO SCARTOZZI; Michela Del Prete; Italo Bearzi; Laura Belvederesi; Francesca Bianchi; Maristella Bianconi; Alessandro Bittoni; Luca Faloppi; Eva Galizia; Riccardo Giampieri; Cristian Loretelli; Alessandra Mandolesi; Mirco Pistelli; Stefano Cascinu
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients.
PloS one 2012;7(7):e38192.
2012: MARIO SCARTOZZI; Simona Alfonsi; Italo Bearzi; Simona Biagetti; Maristella Bianconi; Alessandro Bittoni; Michela Del Prete; Luca Faloppi; Riccardo Giampieri; Lucio Giustini; Cristian Loretelli; Elena Maccaroni; Alessandra Mandolesi; Stefano Cascinu
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.
Journal of translational medicine 2012;10():71.
2012: MARIO SCARTOZZI; Gianluca Svegliati-Baroni; Laura Belvederesi; Maristella Bianconi; Alessandro Bittoni; Michela Del Prete; Luca Faloppi; Riccardo Giampieri; Cristian Loretelli; Elena Maccaroni; Stefano Cascinu
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management.
PloS one 2012;7(3):e32653.
2011: Rossana Berardi; Alessandro Brunelli; Stefano Gasparini; Paola Mazzanti; Azzurra Onofri; Chiara Pierantoni; Eleonora Pisa; Armando Sabbatini; Alfredo Santinelli; MARIO SCARTOZZI; Daniela Stramazzotti; L Zuccatosta; Stefano Cascinu
Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2011;33(4):196-204.
2011: Nicola Battelli; Alessandro Bittoni; Carlo Mariotti; Alessandra Pagliacci; MARIO SCARTOZZI; Laura Zepponi; Stefano Cascinu
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity.
Tumori 2011;97(4):449-53.
2011: Stefano Cascinu; Francesco Ferraù; Eva Galizia; Roberto Labianca; Gabriele Luppi; Francesca Pucci; Rossana Berardi; Giordano Domenico Beretta; Rosa Rita Silva; MARIO SCARTOZZI
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Cancer chemotherapy and pharmacology 2011;68(1):37-43.
2011: MARIO SCARTOZZI; Italo Bearzi; Alessandra Mandolesi; R Giampieri; L Faloppi; Eva Galizia; Fotios Loupakis; alberto zaniboni; Fausto Zorzi; T Biscotti; Roberto Labianca; Alfredo Falcone; Stefano Cascinu
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
British journal of cancer 2011;104(11):1786-90.
2011: Mirco Pistelli; MARIO SCARTOZZI; Rossana Berardi; Alessandro Bittoni; Eva Galizia; Stefano Cascinu
Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice.
Tumori 2011;97(3):275-9.
2011: Luca Faloppi; MARIO SCARTOZZI; Elena Maccaroni; Marzia Di Pietro Paolo; Rossana Berardi; Michela Del Prete; Stefano Cascinu
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
Cancer treatment reviews 2011;37(3):169-77.
2011: MARIO SCARTOZZI; C Loretelli; Italo Bearzi; Alessandra Mandolesi; Eva Galizia; A Onofri; M Pistelli; A Bittoni; Rossana Berardi; Stefano Cascinu
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(4):897-902.
2011: MARIO SCARTOZZI; Walter Siquini; Eva Galizia; Pierpaolo Stortoni; Cristina Marmorale; Rossana Berardi; Aroldo Fianchini; Stefano Cascinu
The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2011;43(3):194-8.
2011: MARIO SCARTOZZI; Maristella Bianconi; Elena Maccaroni; Riccardo Giampieri; Michela Del Prete; Rossana Berardi; Stefano Cascinu
State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Discovery medicine 2011;11(57):144-53.
2011: MARIO SCARTOZZI; Elena Maccaroni; Riccardo Giampieri; Mirco Pistelli; Alessandro Bittoni; Michela Del Prete; Rossana Berardi; Stefano Cascinu
5-Fluorouracil pharmacogenomics: still rocking after all these years?
Pharmacogenomics 2011;12(2):251-65.
2011: MARIO SCARTOZZI; Alessandra Mandolesi; Riccardo Giampieri; Alessandro Bittoni; Chiara Pierantoni; alberto zaniboni; Eva Galizia; Lucio Giustini; Rosa Rita Silva; Renato Bisonni; Rossana Berardi; Tommasina Biscotti; Simona Biagetti; Italo Bearzi; Stefano Cascinu
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
The oncologist 2011;16(1):53-60.
2010: MARIO SCARTOZZI; Alessandra Mandolesi; Riccardo Giampieri; Chiara Pierantoni; Fotios Loupakis; alberto zaniboni; Eva Galizia; Lucio Giustini; Rosa Rita Silva; Renato Bisonni; Rossana Berardi; Simona Biagetti; Stefano Menzo; Alfredo Falcone; Italo Bearzi; Stefano Cascinu
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
International journal of cancer. Journal international du cancer 2010;127(8):1941-7.
2010: MARIO SCARTOZZI; Maristella Bianconi; Elena Maccaroni; Riccardo Giampieri; Rossana Berardi; Stefano Cascinu
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.
Current opinion in molecular therapeutics 2010;12(3):361-71.
2010: Giordano Domenico Beretta; MARIO SCARTOZZI; Luca Tondulli; Stefano Cascinu
Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):e268-9; author reply e270.
2010: MARIO SCARTOZZI; Paola Mazzanti; Riccardo Giampieri; Rossana Berardi; Eva Galizia; S Gasparini; L Zuccatosta; Stefano Cascinu
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
Lung cancer (Amsterdam, Netherlands) 2010;68(3):433-7.
2010: MARIO SCARTOZZI; Mirco Pistelli; Alessandro Bittoni; Riccardo Giampieri; Eva Galizia; Rossana Berardi; Luca Faloppi; Michela Del Prete; Stefano Cascinu
Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy.
Current oncology reports 2010;12(3):175-85.
2010: A Bittoni; E Maccaroni; MARIO SCARTOZZI; Rossana Berardi; Stefano Cascinu
Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives.
European review for medical and pharmacological sciences 2010;14(4):309-14.
2010: MARIO SCARTOZZI; Gianluca Svegliati Baroni; Luca Faloppi; Marzia Di Pietro Paolo; Chiara Pierantoni; R Candelari; Rossana Berardi; Stefania Antognoli; Cinzia Mincarelli; Andrea Risaliti; Cristina Marmorale; Ettore Antico; Antonio Benedetti; Stefano Cascinu
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis.
Journal of experimental & clinical cancer research : CR 2010;29():164.
2010: Rossana Berardi; Azzurra Onofri; Mirco Pistelli; Elena Maccaroni; MARIO SCARTOZZI; Chiara Pierantoni; Stefano Cascinu
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.
Core evidence 2010;5():61-76.
2009: MARIO SCARTOZZI; Italo Bearzi; Alessandra Mandolesi; Eva Galizia; Chiara Pierantoni; Fotios Loupakis; Rossana Berardi; alberto zaniboni; Antonello Quadri; Fausto Zorzi; Simona Biagetti; Cristian Loretelli; Tommasina Biscotti; Roberto Labianca; Gianluca Masi; Alfredo Falcone; Stefano Cascinu
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2009;31(6):417-23.
2009: Rossana Berardi; Giovanna Mantello; MARIO SCARTOZZI; Stefano Del Prete; Gabriele Luppi; Roberto Martinelli; Marco Fumagalli; Filippo Grillo Ruggieri; Italo Bearzi; Alessandra Mandolesi; Cristina Marmorale; Stefano Cascinu
Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome.
International journal of radiation oncology, biology, physics 2009;75(5):1437-43.
2009: Rossana Berardi; Elena Maccaroni; Azzurra Onofri; Riccardo Giampieri; Mirco Pistelli; Alessandro Bittoni; MARIO SCARTOZZI; Chiara Pierantoni; Alessandra Mandolesi; Italo Bearzi; Stefano Cascinu
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2.
Expert opinion on pharmacotherapy 2009;10(15):2467-78.
2009: Rossana Berardi; Elena Maccaroni; Azzurra Onofri; Riccardo Giampieri; Alessandro Bittoni; Mirco Pistelli; MARIO SCARTOZZI; Chiara Pierantoni; Maristella Bianconi; Stefano Cascinu
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1.
Expert opinion on pharmacotherapy 2009;10(14):2245-58.
2009: MARIO SCARTOZZI; Alessandro Bittoni; Mirco Pistelli; Eva Galizia; Rossana Berardi; Riccardo Giampieri; Luca Faloppi; Stefano Cascinu
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives.
Cancer treatment reviews 2009;35(5):451-62.
2009: Fotios Loupakis; Luca Pollina; Irene Stasi; Annamaria Ruzzo; MARIO SCARTOZZI; Daniele Santini; Gianluca Masi; Graziano Francesco; Chiara Cremolini; Eliana Rulli; Emanuele Canestrari; Niccola Funel; Gaia Schiavon; Iacopo Petrini; Mauro Magnani; Giuseppe Tonini; Daniela Campani; Irene Floriani; Stefano Cascinu; Alfredo Falcone
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2622-9.
2009: Rossana Berardi; Lorena Verdecchia; Marzia Di Pietro Paolo; Riccardo Giampieri; MARIO SCARTOZZI; Chiara Pierantoni; Maristella Bianconi; Paola Mazzanti; Stefano Cascinu
Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review.
Critical reviews in oncology/hematology 2009;69(3):223-36.
2009: MARIO SCARTOZZI; Italo Bearzi; Alessandra Mandolesi; Chiara Pierantoni; Fotios Loupakis; alberto zaniboni; Francesca Negri; Antonello Quadri; Fausto Zorzi; Eva Galizia; Rossana Berardi; Tommasina Biscotti; Roberto Labianca; Gianluca Masi; Alfredo Falcone; Stefano Cascinu
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
BMC cancer 2009;9():303.
2008: Chiara Pierantoni; Alessandra Pagliacci; MARIO SCARTOZZI; Rossana Berardi; Maristella Bianconi; Stefano Cascinu
Pancreatic cancer: progress in cancer therapy.
Critical reviews in oncology/hematology 2008;67(1):27-38.
2008: Stefano Cascinu; Rossana Berardi; Stefania Salvagni; Giordano D Beretta; Vincenzo Catalano; Francesca Pucci; Alberto Sobrero; Pierosandro Tagliaferri; Roberto Labianca; MARIO SCARTOZZI; F Crocicchio; E Mari; Andrea Ardizzoni
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
British journal of cancer 2008;98(1):71-6.
2008: Monica Amati; Marco Tomasetti; MARIO SCARTOZZI; Laura Mariotti; Renata Alleva; Elettra Pignotti; Battista Borghi; Matteo Valentino; Mario Governa; Jiri Neuzil; Lory Santarelli
Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(1):163-70.
2008: Stefano Cascinu; Rossana Berardi; Roberto Labianca; Salvatore Siena; Alfredo Falcone; Enrico Aitini; Sandro Barni; Francesco Di Costanzo; Elisa Dapretto; Giuseppe Tonini; Chiara Pierantoni; Salvatore Artale; Silvia Rota; Irene Floriani; MARIO SCARTOZZI; alberto zaniboni
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
The lancet oncology 2008;9(1):39-44.
2007: Stefano Cascinu; MARIO SCARTOZZI; Giovanna Carbonari; Chiara Pierantoni; Lorena Verdecchia; Cinzia Mariani; Michela Squadroni; Stefania Antognoli; Rosa Rita Silva; Riccardo Giampieri; Rossana Berardi
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
American journal of clinical oncology 2007;30(5):526-30.
2007: MARIO SCARTOZZI; Italo Bearzi; Chiara Pierantoni; Alessandra Mandolesi; Fotios Loupakis; alberto zaniboni; Vincenzo Catalano; Antonello Quadri; Fausto Zorzi; Rossana Berardi; Tommasina Biscotti; Roberto Labianca; Alfredo Falcone; Stefano Cascinu
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3930-5.
2007: MARIO SCARTOZZI; Italo Bearzi; Rossana Berardi; Alessandra Mandolesi; Chiara Pierantoni; Stefano Cascinu
Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.
British journal of cancer 2007;97(1):92-7.
2007: Stefano Cascinu; alberto zaniboni; MARIO SCARTOZZI; Fausto Meriggi
Molecular biology for stage II colorectal cancer: the jury is still out.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2861; author reply 2862-3.
2007: MARIO SCARTOZZI; Eva Galizia; Lorena Verdecchia; Rossana Berardi; Stefania Antognoli; Silvia Chiorrini; Stefano Cascinu
Chemotherapy for advanced gastric cancer: across the years for a standard of care.
Expert opinion on pharmacotherapy 2007;8(6):797-808.
2006: Rossana Berardi; Chiara Braconi; Giovanna Mantello; MARIO SCARTOZZI; S Del Prete; Gabriele Luppi; R Martinelli; M Fumagalli; Gianluca Valeri; Italo Bearzi; C Marmovale; F Grillö-Ruggieri; Stefano Cascinu
Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(11):1661-4.
2006: MARIO SCARTOZZI; Alfredo Falcone; Francesca Pucci; Chiara Braconi; Chiara Pierantoni; Luigi Cavanna; Vittorio Franciosi; Rossana Berardi; Giordano D Beretta; Gianluca Masi; Giacomo Allegrini; alberto zaniboni; Roberto Labianca; Stefano Cascinu
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer.
Tumori 2006;92(5):384-8.
2006: MARIO SCARTOZZI; Eva Galizia; Lorena Verdecchia; Rossana Berardi; Graziano Francesco; Vincenzo Catalano; Paolo Giordani; Davide Mari; Rosa Rita Silva; Cristina Marmorale; C Zingaretti; Stefano Cascinu
Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients.
British journal of cancer 2006;95(4):445-9.
2006: Rossana Berardi; Berardi Rossana; MARIO SCARTOZZI; Scartozzi Mario; Federica Freddari; Freddari Federica; Michela Squadroni; Squadroni Michela; Alfredo Santinelli; Santinelli Alfredo; Italo Bearzi; Bearzi Italo; Guidalberto Fabris; Fabris Guidalberto; Stefano Cascinu; Cascinu Stefano
Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.
Cancer treatment reviews 2006;32(5):333-47.
2006: MARIO SCARTOZZI; Vittorio Franciosi; Nicoletta Campanini; Giovanni Benedetti; Fausto Barbieri; Giulio Rossi; Rossana Berardi; Roberta Camisa; Rosa Rita Silva; Alfredo Santinelli; Andrea Ardizzoni; Lucio Crinò; Guido Rindi; Stefano Cascinu
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.
Lung cancer (Amsterdam, Netherlands) 2006;53(1):103-9.
2006: Stefano Cascinu; Lorena Verdecchia; N Valeri; Rossana Berardi; MARIO SCARTOZZI
New target therapies in advanced pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v148-52.
2006: MARIO SCARTOZZI; Chiara Pierantoni; Rossana Berardi; Stefania Antognoli; Italo Bearzi; Stefano Cascinu
Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2006;28(2):61-8.
2006: MARIO SCARTOZZI; Chiara Pierantoni; Rossana Berardi; Michela Squadroni; Stefano Cascinu
Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.
Expert opinion on therapeutic targets 2006;10(2):281-7.
2005: Rossana Berardi; G Grilli; E Romagnoli; T Saladino; Federica Freddari; T Tamburrano; Eva Galizia; G Carbonari; C Mariani; Chiara Braconi; Chiara Pierantoni; Nicola Battelli; MARIO SCARTOZZI; Stefano Cascinu
[Paraneoplastic syndromes: a review].
La Clinica terapeutica 2005;156(6):281-8.
2005: Rossana Berardi; Tiziana Saladino; Davide Mari; Rosa Rita Silva; MARIO SCARTOZZI; Lorena Verdecchia; Azzurra Onofri; Stefano Cascinu
Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy.
Tumori 2005;91(6):463-6.
2005: Rossana Berardi; Alessandro Brunelli; T Tamburrano; Lorena Verdecchia; A Onofri; L Zuccatosta; S Gasparini; Alfredo Santinelli; MARIO SCARTOZZI; Gianluca Valeri; Andrea Giovagnoni; Gian Marco Giuseppetti; Guidalberto Fabris; Cristina Marmorale; Aroldo Fianchini; Stefano Cascinu
Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers.
Lung cancer (Amsterdam, Netherlands) 2005;49(3):371-6.
2005: MARIO SCARTOZZI; Rossana Berardi; Chiara Pierantoni; Stefano Cascinu
Pre-operative treatment modalities in gastric cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 4():iv106-109.
2005: Graziano Francesco; Annamaria Ruzzo; Daniele Santini; Bostjan Humar; Giuseppe Tonini; Vincenzo Catalano; Rossana Berardi; Francesca Pizzagalli; Federica Arduini; Italo Bearzi; MARIO SCARTOZZI; Stefano Cascinu; Enrica Testa; Rita Ficarelli; Mauro Magnani
Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2339-45.
2005: MARIO SCARTOZZI; Eva Galizia; Graziano Francesco; Vincenzo Catalano; Rossana Berardi; Anna Maria Baldelli; Enrica Testa; Davide Mari; Rosa Rita Silva; Stefano Cascinu
Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients.
British journal of cancer 2005;92(6):1051-4.
2005: MARIO SCARTOZZI; Alberto Sobrero; G Gasparini; Rossana Berardi; Vincenzo Catalano; Graziano Francesco; Sandro Barni; alberto zaniboni; Giordano D Beretta; Roberto Labianca; Stefano Cascinu
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Oncology 2005;68(2-3):212-6.
2005: Rossana Berardi; Lorena Verdecchia; MARIO SCARTOZZI; Stefano Cascinu
New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols.
JOP : Journal of the pancreas 2005;6(1 Suppl):118-21.
2004: MARIO SCARTOZZI; Italo Bearzi; Rossana Berardi; Alessandra Mandolesi; Guidalberto Fabris; Stefano Cascinu
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4772-8.
2004: Eva Galizia; Rossana Berardi; MARIO SCARTOZZI; Stefano Cascinu
A cost-benefit analysis of chemotherapy for gastric cancer.
Expert opinion on pharmacotherapy 2004;5(10):2109-14.
2004: MARIO SCARTOZZI; Eva Galizia; Federica Freddari; Rossana Berardi; Riccardo Cellerino; Stefano Cascinu
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches.
Cancer treatment reviews 2004;30(5):451-9.
2004: Graziano Francesco; Alessandra Mandolesi; Annamaria Ruzzo; Italo Bearzi; Enrica Testa; Federica Arduini; Rosarita Silva; Pietro Muretto; Davide Mari; Rossana Berardi; MARIO SCARTOZZI; Vittorio Lai; Stefano Cascinu; Mauro Magnani
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(3):106-10.
2004: Stefano Cascinu; MARIO SCARTOZZI; Roberto Labianca; Vincenzo Catalano; Rosa Rita Silva; Sandro Barni; alberto zaniboni; A D'Angelo; Stefania Salvagni; Giancarlo Martignoni; Giordano D Beretta; Graziano Francesco; Rossana Berardi; Vittorio Franciosi
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
British journal of cancer 2004;90(8):1521-5.
2004: Rossana Berardi; MARIO SCARTOZZI; Emanuela Romagnoli; Stefania Antognoli; Stefano Cascinu
Gastric cancer treatment: a systematic review.
Oncology reports 2004;11(4):911-6.
2004: Federica Freddari; Rossana Berardi; MARIO SCARTOZZI; Stefano Cascinu
[Non-small cell lung carcinoma: pathology, biology and prognosis].
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2004;3(2):S3-4.
2004: Graziano Francesco; Federica Arduini; Annamaria Ruzzo; Alessandra Mandolesi; Italo Bearzi; Rosarita Silva; Pietro Muretto; Enrica Testa; Davide Mari; Mauro Magnani; MARIO SCARTOZZI; Stefano Cascinu
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(3):489-92.
2003: Rossana Berardi; MARIO SCARTOZZI; Eva Galizia; Stefano Cascinu
Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature.
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2003;2(5):S45-7.
2003: Rossana Berardi; Luciano Latini; Alfredo Santinelli; N Herber; S Baldassarre; MARIO SCARTOZZI; Riccardo Cellerino
Mucocele-like tumour of the breast.
Journal of experimental & clinical cancer research : CR 2003;22(2):329-32.
2003: MARIO SCARTOZZI; M De Nictolis; Eva Galizia; P Carassai; Francesca Bianchi; Rossana Berardi; Rosaria Gesuita; Andrea Piga; Riccardo Cellerino; Emilio Porfiri
Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1144-9.
2003: Rossana Berardi; Emilio Porfiri; MARIO SCARTOZZI; Paolo Lippe; Rosa Rita Silva; D Nacciarriti; Ettore Tito Menichetti; Diego Tummarello; Flavia Carle; Andrea Piga; Riccardo Cellerino
Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine.
Oncology 2003;65(3):198-203.
2002: MARIO SCARTOZZI; Francesca Bianchi; Saverio Rosati; Eva Galizia; Annalisa Antolini; Cristian Loretelli; Andrea Piga; Italo Bearzi; Riccardo Cellerino; Emilio Porfiri
Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1203-8.
2000: Cristian Massacesi; Romeo Bascioni; Riccardo Cellerino; MARIO SCARTOZZI; Raffaella Bracci; Paolo Alessandroni; Stefania Antognoli; Andrea Ciavattini; M De Nictolis; Andrea Piga
Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Journal of experimental & clinical cancer research : CR 2000;19(1):13-6.
1998: Stefano Cascinu; Vincenzo Catalano; Anna Maria Baldelli; MARIO SCARTOZZI; Nicola Battelli; Graziano Francesco; Riccardo Cellerino
Locoregional treatments of unresectable liver metastases from colorectal cancer.
Cancer treatment reviews 1998;24(1):3-14.
1997: Stefano Cascinu; Vincenzo Catalano; MARIO SCARTOZZI; Anna Maria Baldelli; Riccardo Cellerino
Liver metastases from colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(4):393-9.